CN1368503A - Safflower lyochrome rich in carthamin A, its preparing process, its preparation and its medical usage - Google Patents
Safflower lyochrome rich in carthamin A, its preparing process, its preparation and its medical usage Download PDFInfo
- Publication number
- CN1368503A CN1368503A CN 01131268 CN01131268A CN1368503A CN 1368503 A CN1368503 A CN 1368503A CN 01131268 CN01131268 CN 01131268 CN 01131268 A CN01131268 A CN 01131268A CN 1368503 A CN1368503 A CN 1368503A
- Authority
- CN
- China
- Prior art keywords
- carthamin yellow
- parts
- carthamin
- medicine
- medicine according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A safflower lyochrome rich is carthamin A (80-100%) and its preparing process and application to preparation of medicines to prevent and cure cardiovascular and cerebrovascular ischemia, and its medicines and preparing process are also disclosed.
Description
Technical field
The present invention relates to a kind of carthamin yellow that is rich in HONGHUAMINGGAN A and preparation method thereof, the invention still further relates to the purposes of this carthamin yellow as effective constituent preparation treatment cardiac-cerebral ischemia diseases medicine, in addition, the pharmaceutical preparation that contains this carthamin yellow and their method for making have been the invention still further relates to.
Background technology
Safflower is the dried floral of feverfew safflower (Carthamus tinctorius L.), is the blood-activating stasis-removing kind Chinese medicine of using always, and carthamin yellow is the water-soluble flavone compounds that has function of promoting blood circulation to disperse blood clots in the safflower.The preparation of relevant carthamin yellow and chemical constitution report differ, bibliographical information the earliest adopts the aqueous extract chromatography of cellulose chromatography with safflower, is divided into carthamin yellow I, the carthamin yellow II of brown ceramic powder, the carthamin yellow III of yellowish brown powder and four column chromatography sections of carthamin yellow IV (seeing " Shanxi medical magazine " 1980 the 9th volumes the 1st phase 2-8 page or leaf) of brown syrup shape thing of brown-black powder.Lu Zhengwu etc. have reported and have contained 75% HONGHUAMINGGAN A and 15% carthamin yellow III, surplus is the carthamin yellow that carthamin yellow II and IV form, and the safflomin A of reports in 1981 such as the chemical structure that proposes HONGHUAMINGGAN A and Onodera is consistent, but to the unexposed report of its preparation method (see " Acta Pharmacologica Sinica " rolled up the 6th phase 537-542 page or leaf in 1991 the 12nd).Pharmacological action to Flos Carthami total flavochromes also has many reports, as the Flos Carthami total flavochromes of reports such as the Lu Zhengwu restraining effect (seeing " Acta Pharmacologica Sinica " 1991 the 12nd volumes the 6th phase 537-542 page or leaf) to immunologic function; Just good hypotensive effect (seeing " Chinese patent medicine research " the 7th phase 27-29 page or leaf in 1986) and the stronger and persistent analgesic effect (seeing " herbal medicine " 1984 the 15th volumes the 8th phase 12-14 page or leaf) of having reported Flos Carthami total flavochromes that wait of Huang also has effects such as antithrombotic formation and anti-hypoxia in addition.Gao Qiming has reported and has caused the acute ischemia anoxic brain damage that obvious provide protection (seeing " combination of Chinese tradiational and Western medicine magazine " 1984 the 4th volumes the 12nd phase 758-760 page or leaf) is arranged after safflower is to the rat carotid artery ligation.After the extraction of the Flos Carthami total flavochromes of bibliographical information and separation method were water extract-alcohol precipitation, by the SephadeLH-20 column chromatography, water was eluent, the Flos Carthami total flavochromes that the repeated treatments purifying obtains (seeing " herbal medicine " nineteen ninety the 21st volume the 4th phase 44-45 page or leaf).Although the purposes that also discloses a kind of carthamin yellow and extracting method thereof among the CN1272500A and be used for the treatment of or prevent multiple cardiovascular and cerebrovascular diseases, the content of measuring HONGHUAMINGGAN A in the carthamin yellow of finding the preparation of extracting method described in this invention through us is lower.The inventor is surprised to find under study for action; the content of HONGHUAMINGGAN A in carthamin yellow to its protection and the treatment using of cardiac-cerebral ischemia diseases have a direct impact, thereby thereby be developed into a kind of to the prevention and the treatment cardiac-cerebral ischemia diseases have the carthamin yellow that is rich in HONGHUAMINGGAN A of better curative effect to finish the present invention.
Summary of the invention
The invention provides a kind of carthamin yellow that is rich in HONGHUAMINGGAN A and preparation method thereof with its in the purposes aspect preparation treatment and the prevention cardiac-cerebral ischemia medicine.
In the carthamin yellow of the present invention the content of HONGHUAMINGGAN A more than or equal to 80% less than 100% (weight), less than 100%, all the other compositions in the carthamin yellow wherein of the present invention are other pigment to the content that is preferably HONGHUAMINGGAN A in the carthamin yellow more than or equal to 90%.
Carthamin yellow of the present invention can obtain by following method:
1) with safflower water cold soaking 24 hours or decocted refluxing extraction 50-90 minute, to filter then, it is 1.10-1.25 that filtrate is concentrated into relative density;
2) adding ethanol in the concentrated solution is measured 80% to containing alcohol, and constantly stir, precipitate 24 hours at 4 ℃, remove by filter precipitation, get supernatant liquor, waving clean ethanol and being concentrated into relative density is 1.15-1.20:
3) in concentrated solution, add 5-10 water doubly, precipitate 12-24 hour, the centrifugal precipitation of removing at 4 ℃;
4) with above-mentioned centrifugate through macroporous adsorbent resin column chromatography, earlier be eluted to the Molish reaction and ninhydrin reaction is negative with deionized water, continuation is with 4-6 column volume of deionized water wash-out and collect elutriant then;
5) above-mentioned elutriant is adsorbed through polymeric amide, the polar solvent wash-out is collected elutriant, removes eluting solvent at 60 ℃ of concentrating under reduced pressure, remaining aqueous solution lyophilize or spraying drying, obtains the orange amorphous powder, i.e. carthamin yellow.
Present method is preferably: get the safflower crude drug and add its weight 10-15 water doubly, boiled 50 minutes, filter, it is 1.25 that filtrate is concentrated into relative density, adds ethanol to containing alcohol amount 80%, precipitates 24 hours at 4 ℃, filter, filtrate is concentrated into relative density 1.20, adds the water of 10 times of amounts, precipitates 24 hours at 4 ℃, centrifugal, getting supernatant liquor, is the absorption with macroporous adsorbent resin of its 40% (crude drug amount) with weight, with 3 column volumes of deionized water wash-out, continue then with 5 column volumes of deionized water wash-out, collecting elutriant, is the polymeric amide absorption of its 10% (crude drug amount) with weight, is washed till earlier colourless with deionized water, wash 8 column volumes with 95% ethanol then, collect elutriant, concentrate on the rotatory evaporator and remove ethanol, lyophilize obtains carthamin yellow.
Owing to use water as the extraction solvent in the aforesaid method, nontoxic, adsorbents adsorb, ethanol elution, wherein used solvent is water and ethanol, all belongs to the solvent that routine is easy to get, and equipment also is common equipment, so the advantage of this method is that cost is low, step is simple, less energy consumption, production safety and pollution-free, so stronger industrial usability is arranged; And the present invention can make the content of the bright glycosides of safflower in the carthamin yellow reach more than 80%, and this also is that technology was reported as yet in the past, because the increase of HONGHUAMINGGAN A content, thereby improved curative effect of medication, satisfied the demand of people's medications.
Certainly aforesaid method is not unique, be a kind of indefiniteness for example, the present invention also comprised other any make the ratio of HONGHUAMINGGAN A in carthamin yellow more than or equal to 80% less than any extracting method of 100%.
Carthamin yellow of the present invention obviously is better than the curative effect (seeing test example 2) of Flos Carthami injection described in the prior art in the effect of treatment and prevention cardiac-cerebral ischemia diseases.Confirming that through test the medium lethal dose of carthamin yellow of the present invention is 5g/kg, aspect the treatment cardiac-cerebral ischemia, is 5-8mg/kg to the effective dose of rat, is 0.5-2mg/kg to people's effective dose.Carthamin yellow of the present invention has new purposes at the medicine of preparation treatment and prevention cardiac-cerebral ischemia.
Carthamin yellow of the present invention can be made the medicine of various formulations with acceptable accessories as effective constituent, as injection liquid, infusion solutions, Injectable sterile lyophilized injectable powder, tablet, capsule or oral liquid etc.
The preparation of the injection liquid of carthamin yellow of the present invention, the carthamin yellow with significant quantity dissolves with water for injection exactly, through molecular weight cut-off be 10000 daltonian tubular fibre membrane ultrafiltration with degerming and remove pyrogen, filling and sealing is promptly.
The preparation of the aseptic freeze-dried powder injection of carthamin yellow of the present invention is to select for use pharmaceutical excipients such as aqueous solution for injection balustrade such as N.F,USP MANNITOL, low molecular dextran, sucrose to guarantee the instantly-soluble of this preparation.With the carthamin yellow of significant quantity and balustrade through dissolving with water for injection, through molecular weight cut-off is that 10000 daltonian tubular fibre membrane ultrafiltration are with degerming and remove pyrogen, can, first then pre-freeze is to-55-35 ℃, be incubated 1-4 hour, begin to vacuumize, in 15-30 hour, temperature is risen to 10-30 ℃, continue to vacuumize and promptly made in 3-10 hour.
The tablet of carthamin yellow of the present invention and capsule each component total amount proportioning are: safflower red pigment 10-15 part, dextrin 30-40 part, starch 50-60 part, 5 parts of lactose, secondary calcium phosphate 2-4 part, Magnesium Stearate 1.5-3 part are adopted conventional pressed disc method to make tablet or said components incapsulated and are made capsule.Wherein being preferably 10 parts of carthamin yellows, 30 parts in dextrin, 30 parts of starch, 5 parts of lactose, 2 parts of Calcium hydrogen carbonates and Magnesium Stearate mixes for 1.5 parts, add the entry boiling granulating, whole grain sieves, in incapsulating, make capsule, add Magnesium Stearate greater than 14 purposes and make tablet less than 14 purpose particles; Being preferably 15 parts of carthamin yellows, 40 parts in dextrin, 60 parts of starch, 5 parts of lactose, 4 parts of Calcium hydrogen carbonates and Magnesium Stearate again mixes for 3 parts, add the entry boiling granulating, sieve whole, in incapsulating, make capsule, add Magnesium Stearate greater than 14 purposes and make tablet less than 14 purpose particles.
The present invention is further illustrated with the test example by the following examples, but the present invention is not limited to this embodiment, and in these embodiments unless otherwise indicated, its all umbers and proportioning are all by weight.
Get the safflower crude drug, add 10-15 times of water of its weight, boiled 90 minutes, filter, it is 1.12 that filtrate decompression is concentrated into relative density, adding ethanol is 80%, 4 ℃ of precipitation 24 hours to containing the alcohol amount, filters, it is 1.15 that filtrate filtrate is concentrated into relative density, the water that adds 10 times of amounts, 4 ℃ precipitate 12 hours, centrifugal, get supernatant liquor, with weight is its D101 absorption with macroporous adsorbent resin of 30%, with 2 column volumes of deionized water wash-out, continues then with 4 column volumes of deionized water wash-out, collect elutriant, with weight is its polymeric amide of 5% absorption, and elder generation is washed till colourless with deionized water, wash 8 column volumes with 95% ethanol then, collect elutriant, concentrate on the rotatory evaporator and remove ethanol, lyophilize obtains carthamin yellow, surveys the wherein content 85% of HONGHUAMINGGAN A.
Get the safflower crude drug, add 10-15 times of water of its weight, boiled 70 minutes, filter, it is 1.20 that filtrate decompression is concentrated into relative density, adding ethanol is 80%, 4 ℃ of precipitation 24 hours to containing the alcohol amount, filters, it is 1.10 that filtrate filtrate is concentrated into relative density, the water that adds 10 times of amounts, 4 ℃ precipitate 24 hours, centrifugal, get supernatant liquor, with weight is its D101 absorption with macroporous adsorbent resin of 40%, with 3 column volumes of deionized water wash-out, continues then with 5 column volumes of deionized water wash-out, collect elutriant, with weight is its polymeric amide of 10% absorption, and elder generation is washed till colourless with deionized water, wash 8 column volumes with 95% ethanol then, collect elutriant, concentrate on the rotatory evaporator and remove ethanol, lyophilize obtains carthamin yellow, and the content of surveying HONGHUAMINGGAN A is 90%.
Get the safflower crude drug, add 10-15 times of water of its weight, boiled 50 minutes, filter, it is 1.25 that filtrate decompression is concentrated into relative density, adding ethanol is 80%, 4 ℃ of precipitation 24 hours to containing the alcohol amount, filters, it is 1.20 that filtrate filtrate is concentrated into relative density, the water that adds 10 times of amounts, 4 ℃ precipitate 24 hours, centrifugal, get supernatant liquor, with weight is its D101 absorption with macroporous adsorbent resin of 40%, with 3 column volumes of deionized water wash-out, continues then with 5 column volumes of deionized water wash-out, collect elutriant, with weight is its polymeric amide of 10% absorption, and elder generation is washed till colourless with deionized water, wash 8 column volumes with 95% ethanol then, collect elutriant, concentrate on the rotatory evaporator and remove ethanol, lyophilize obtains carthamin yellow, and the content of surveying HONGHUAMINGGAN A is 98%.
The preparation of aseptic freeze-dried powder injection
Get the foregoing description 1 resulting safflower red pigment 10g, medicinal N.F,USP MANNITOL 40g is dissolved in the distilled water for injection of 2000ml, through molecular weight cut-off be 10000 daltonian tubular fibre membrane ultrafiltration with the degerming depyrogenation, 1000 of cans, promptly aseptic freeze-dried.
Get the foregoing description 2 resulting carthamin yellow 10g, medicinal dextran 20g is dissolved in the distilled water for injection of 2000ml, through molecular weight cut-off be 10000 daltonian tubular fibre membrane ultrafiltration with the degerming depyrogenation, 1000 of cans, promptly aseptic freeze-dried.
Embodiment 6
Get the foregoing description 3 resulting safflower red pigment 10g, pharmaceutical lactose 40g is dissolved in the distilled water for injection of 2000ml, through molecular weight cut-off be 10000 daltonian tubular fibre membrane ultrafiltration with the degerming depyrogenation, 1000 of cans, promptly aseptic freeze-dried.
Embodiment 7
Get the foregoing description 1 resulting safflower red pigment 10g, be dissolved in the distilled water for injection of 2000ml, through molecular weight cut-off be 10000 daltonian tubular fibre membrane ultrafiltration with the degerming depyrogenation, 1000 of cans are promptly.
Embodiment 8
Get the foregoing description 3 resulting safflower red pigment 30g, be dissolved in the physiological saline of 250L, through molecular weight cut-off be 10000 daltonian tubular fibre membrane ultrafiltration with the degerming depyrogenation, 1000 bottles of cans are promptly.
Embodiment 9
Get 10 parts of the foregoing description 2 resulting safflower red pigments, 30 parts in dextrin, 50 parts of starch, 5 parts of lactose, 1.5 parts of Calcium hydrogen carbonates mix, and add the entry boiling granulating, sieve whole, make capsule in the shell, add Magnesium Stearate greater than 14 purposes and make tablet incapsulating less than 14 purpose particles.
Embodiment 10
Get 15 parts of the foregoing description 3 resulting safflower red pigments, 40 parts in dextrin, 60 parts of starch, 5 parts of lactose, 4 parts of Calcium hydrogen carbonates, 3 parts of Magnesium Stearates, mix, add the entry boiling granulating, whole grain sieves, make capsule in the shell incapsulating, add Magnesium Stearate greater than 14 purposes and make tablet less than 14 purpose particles.
The preparation method of test example 1. embodiment of the invention 1 and the comparison test of prior art
Material and condition:
The carthamin yellow that polymeric amide chromatography legal system is equipped with: according to the carthamin yellow that the 2 described polymeric amide chromatography legal systems of embodiment among the CN 1272500A are equipped with, the polymeric amide of wherein selecting for use is that Changzhou is celebrated chemical plant production, specification 60 orders forever.
The carthamin yellow of silica gel adsorption preparation: according to the carthamin yellow of the 5 described silica gel adsorption preparations of embodiment among the CN 1272500A.
The carthamin yellow of macroreticular resin absorbing method preparation: according to the carthamin yellow of the 8 described macroreticular resin absorbing method preparations of embodiment among the CN 1272500A, the macroporous resin of wherein selecting for use is D-101, and Chemical Plant of Nankai Univ. produces.
Thin layer is differentiated:
Polymeric amide thin layer plate: the biochemical plastic molding and processing plant of Taizhou, Zhejiang city road and bridge tetramethyl
Developping agent: 30% acetic acid Rf=0.7
High performance liquid phase detects:
The source of reference substance
The HONGHUAMINGGAN A reference substance is separated from safflower by Shandong Province's natural drug Engineering Technical Research Centre and obtains, and adopts methods such as ultraviolet, infrared, mass spectrum, nuclear-magnetism to prove conclusively structure, and its high performance liquid phase purity is greater than 98%.
Chromatographic condition
Instrument: SpectraSYSTEM1000 chromatogram pump; Spectra100 UV-detector (TSP company; U.S.A); The star workstation of CHROMTEK analysis; Chromatographic column: DiscoveryC18 (25cm * 4.6mm; 5 micron); Methyl alcohol-acetonitrile-0.2% phosphoric acid (345: 25: 630) is moving phase; The detection wavelength is 400nm.
Linear relationship and linearity range are investigated
Through The effects, HONGHUAMINGGAN A is in 0.058～1.74 μ g concentration range, and peak area and concentration are good linear relationship, r=0.9997.
Measuring method and result
Assay method
The preparation precision of reference substance solution takes by weighing the HONGHUAMINGGAN A reference substance, adds water and makes the solution that every 1ml contains 0.04mg, promptly.
Each about 4mg of gained sample is got in the preparation of need testing solution, and accurate the title decides, and puts respectively in the 100ml measuring bottle, adds water and makes dissolving in right amount and be diluted to scale, shakes up, promptly.
Accurate respectively above-mentioned reference substance solution and each 20 μ l of need testing solution of drawing inject liquid chromatograph, measure, promptly.Measurement result sees Table 1, and thin layer chromatography figure sees Fig. 1.
The assay of HONGHUAMINGGAN A in the carthamin yellow of table 1 Different Extraction Method preparation
| Extraction and separation method | Polymeric amide chromatography method | Macroreticular resin absorbing method | Silica gel adsorption | The inventive method |
| The content of HONGHUAMINGGAN A (%) in the carthamin yellow | ?????3.2 | ???????2.6 | ?????0.6 | ?????86.5 |
The colour developing figure situation of carthamin yellow after the polymeric amide thin layer plate launches of Different Extraction Method preparation seen accompanying drawing (1).
In the accompanying drawing (1),
The carthamin yellow that 1 expression is equipped with according to the 2 described polymeric amide chromatography legal systems of embodiment among the CN 1272500A;
2 expressions are according to the carthamin yellow of the 8 described macroreticular resin absorbing method preparations of embodiment among the CN 1272500A;
3 expressions are according to the carthamin yellow of the 5 described silica gel adsorption preparations of embodiment among the CN 1272500A;
The isolating yellow pigment of 4 expression the inventive method;
The reference substance of 5 expression HONGHUAMINGGAN A.
Conclusion: by above-mentioned experimental result as can be seen: the content of HONGHUAMINGGAN A is apparently higher than the content that uses HONGHUAMINGGAN A in the resulting carthamin yellow of other method in the resulting carthamin yellow of the present invention.
Test example 2: to the influence of rat suppository formation
Animal: Westar rat male and female half and half.
Medicine: blank group (injection physiological saline), Flos Carthami injection (with reference to the method preparation of Drug Standard of Ministry of Public Health of the Peoples Republic of China WS3-B-3825-98), embodiment 7 described injection liquids (containing 80% HONGHUAMINGGAN A), embodiment 8 described injection liquids (containing 98% HONGHUAMINGGAN A).
Method:
32 of rats are divided into two groups of intravenous injection NS groups, Flos Carthami injection group, medicine of the present invention, 8 every group.With reference to the Umetsu method, rats by intraperitoneal injection Sodital (30mg/kg) release yoke arteria carotis communis and left external jugular vein, be full of the polyethylene tube of three sections connections with 50 μ/ml heparin-saline, put into 4 trumpeter's art silk threads of long 7cm in the pipe, left external jugular vein and fork arteria carotis communis are successively inserted in the pipe two ends, behind intravenously administrable or the NS, decontrol bulldog clamp immediately, make blood circulation.Herba Clinopodii in after 15 minutes takes out silk thread and claims wet weight of thrombus.Calculate the inhibiting rate of thrombus by following company:
The results are shown in Table 2.
Table 2
| Group | Dosage (mg/kg) | Animal number of elements (only) | Wet weight of thrombus (mg) (X ± SD) | Inhibiting rate (%) |
| Control group | Deng capacity | ?????8 | ????80.5±8.5 | ????---- |
| Flos Carthami injection | ?????3 | ?????8 | ????50.3±7.2 | ????37.52 |
| Embodiment 7 described injection liquids | ?????3 | ?????8 | ????20.4±6.5 | ????74.66 |
| Embodiment 8 described injection liquids | ?????3 | ?????8 | ????15.8±3.0 | ????80.37 |
As can be seen from Table 2, carthamin yellow of the present invention in suppressing body, the formation of external thrombus is better than existing Flos Carthami injection, and along with the increase of the content of HONGHUAMINGGAN A, effect also improves.
Simultaneously, we pass through behind the rat cerebral ischemia, and animal behavior is observed discovery: ischemia group (control group) nervous symptoms mark is significantly higher than sham operated rats, HONGHUAMINGGAN A can obviously be improved its nervous symptoms, compare with the prior art medicaments injection, significant difference is arranged, and be the content dependency.
We also pass through rat cerebral ischemia after 24 hours, the obvious ischemic region area that cerebral tissue occurs is observed, its ischemic region area reaches 15% of full brain, contain the carthamin yellow pharmacological agent of different concns HONGHUAMINGGAN A after the cerebral ischemia, observe after 24 hours, the embodiment of the invention 7 described injection liquids (containing 80% HONGHUAMINGGAN A) can reduce necrosis area more than 50% with the dosed administration of 3mg/kg, and are higher by 20% than the curative ratio of existing Flos Carthami injection, and are dose-dependently.
Claims (17)
1. carthamin yellow, it is characterized in that the content of HONGHUAMINGGAN A in carthamin yellow more than or equal to 80% less than 100% (weight).
2. carthamin yellow according to claim 1, wherein the content of HONGHUAMINGGAN A in carthamin yellow more than or equal to 90% less than 100% (weight).
3. method for preparing the described carthamin yellow of claim 1, it comprises the following steps:
1) with safflower water cold soaking 24 hours or decocted refluxing extraction 50-90 minute, to filter then, it is 1.10-1.25 that filtrate is concentrated into relative density;
2) adding ethanol in the concentrated solution is measured 80% to containing alcohol, and constantly stir, precipitate 24 hours at 4 ℃, remove by filter precipitation, get supernatant liquor, waving clean ethanol and being concentrated into relative density is 1.15-1.20:
3) in concentrated solution, add 5-10 water doubly, precipitate 12-24 hour, the centrifugal precipitation of removing at 4 ℃;
4) with above-mentioned centrifugate through macroporous adsorbent resin column chromatography, earlier be eluted to the Molish reaction and ninhydrin reaction is negative with deionized water, continuation is with 4-6 column volume of deionized water wash-out and collect elutriant then;
5) above-mentioned elutriant is adsorbed through polymeric amide, the polar solvent wash-out is collected elutriant, removes eluting solvent at 60 ℃ of concentrating under reduced pressure, remaining aqueous solution lyophilize or spraying drying, obtains the orange amorphous powder, i.e. carthamin yellow.
4. the preparation method of carthamin yellow according to claim 3, it comprises: get the safflower crude drug and add its weight 10-15 water doubly, boiled 50 minutes, and filtered, it is 1.25 that filtrate is concentrated into relative density, add ethanol to containing alcohol amount 80%, precipitate 24 hours at 4 ℃, filter, filtrate is concentrated into relative density 1.20, the water that adds 10 times of amounts, precipitate 24 hours at 4 ℃, centrifugal, get supernatant liquor, with weight is the absorption with macroporous adsorbent resin of its 40% (crude drug amount), with 3 column volumes of deionized water wash-out, continue then to collect elutriant with 5 column volumes of deionized water wash-out, with weight is the polymeric amide absorption of its 10% (crude drug amount), elder generation is washed till colourless with deionized water, wash 8 column volumes with 95% ethanol then, collects elutriant, concentrate on the rotatory evaporator and remove ethanol, lyophilize obtains carthamin yellow.
5. medicine that contains claim 1 or 2 described carthamin yellows.
6. medicine according to claim 5, the formulation of its Chinese traditional medicine are injection liquid.
7. medicine according to claim 6, wherein injection liquid can be made by following method: the carthamin yellow of significant quantity is dissolved with water for injection, through molecular weight cut-off be 10000 daltonian tubular fibre membrane ultrafiltration with the degerming depyrogenation, filling and sealing is promptly.
8. medicine according to claim 5, wherein the formulation of this medicine is aseptic freeze-dried powder injection.
9. medicine according to claim 8, its aseptic freeze-dried powder injection can be made by following method: the carthamin yellow and the balustrade of significant quantity are dissolved with water for injection, through molecular weight cut-off is that 10000 daltonian tubular fibre membrane ultrafiltration are with the degerming depyrogenation, can puts into that first pre-freeze is incubated 1-4 hour to-55 ℃～-35 ℃ behind the Freeze Drying Equipment, begin to vacuumize, in 15-30 hour, temperature is risen to 10 ℃～30 ℃, continue to vacuumize and promptly made in 3-10 hour.
10. medicine according to claim 9, wherein balustrade is N.F,USP MANNITOL, low molecular dextran or sucrose.
11. medicine according to claim 5, wherein the formulation of this medicine is tablet or capsule.
12. medicine according to claim 11, its tablet or capsule can be made by following method: carthamin yellow 10-15 part, dextrin 30-40 part, starch 50-60 part, 5 parts of lactose, secondary calcium phosphate 2-4 part, Magnesium Stearate 1.5-3 part; Adopt conventional pressed disc method to make tablet or above-mentioned component incapsulated and make capsule.
13. medicine according to claim 12, its tablet or capsule can be made by following method: 10 parts of carthamin yellows, 30 parts in dextrin, 30 parts of starch, 5 parts of lactose, 2 parts of Calcium hydrogen carbonates and Magnesium Stearate are mixed for 1.5 parts, add the entry boiling granulating, whole grain sieves, in incapsulating, make capsule, add Magnesium Stearate greater than 14 purposes and make tablet less than 14 purpose particles.
14. medicine according to claim 12, its tablet or capsule can be made by following method: 15 parts of carthamin yellows, 40 parts in dextrin, 60 parts of starch, 5 parts of lactose, 4 parts of Calcium hydrogen carbonates and Magnesium Stearate are mixed for 3 parts, add the entry boiling granulating, whole grain sieves, in incapsulating, make capsule, add Magnesium Stearate greater than 14 purposes and make tablet less than 14 purpose particles.
15. medicine according to claim 5, wherein this pharmaceutical dosage form is an infusion solutions.
16. medicine according to claim 16, its infusion solutions can be made by following method: with the carthamin yellow physiological saline solution of significant quantity, through molecular weight cut-off be 10000 daltonian tubular fibre membrane ultrafiltration with the depyrogenation degerming, can is promptly.
17. carthamin yellow according to claim 1 and 2 is in the purposes of preparation treatment or prevention cardiac-cerebral ischemia medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01131268 CN1205216C (en) | 2000-10-30 | 2001-09-05 | Safflower lyochrome rich in carthamin A, its preparing process, its preparation and its medical usage |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00130232 | 2000-10-30 | ||
| CN00130232.9 | 2000-10-30 | ||
| CN 01131268 CN1205216C (en) | 2000-10-30 | 2001-09-05 | Safflower lyochrome rich in carthamin A, its preparing process, its preparation and its medical usage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1368503A true CN1368503A (en) | 2002-09-11 |
| CN1205216C CN1205216C (en) | 2005-06-08 |
Family
ID=25739611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01131268 Expired - Fee Related CN1205216C (en) | 2000-10-30 | 2001-09-05 | Safflower lyochrome rich in carthamin A, its preparing process, its preparation and its medical usage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1205216C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300161C (en) * | 2003-09-22 | 2007-02-14 | 浙江永宁制药厂 | Yellow pigment of safflower preparation method and application |
| CN1301707C (en) * | 2005-03-18 | 2007-02-28 | 邹巧根 | Danhong freeze dried powder injection agent and its preparation method |
| CN1813709B (en) * | 2005-01-31 | 2012-04-18 | 浙江永宁药业股份有限公司 | Safflower yellow dropping pill, and its preparing method and use |
| CN102657691A (en) * | 2012-06-02 | 2012-09-12 | 悦康药业集团安徽天然制药有限公司 | Extraction process of carthamin yellow |
| CN102771885A (en) * | 2011-05-13 | 2012-11-14 | 湖北中烟工业有限责任公司 | Production method of food pigment granules special for coloring tobacco sheets |
| CN103127197A (en) * | 2013-03-21 | 2013-06-05 | 悦康药业集团有限公司 | Preparation method of freeze-drying preparation for safflower yellow injection |
| CN103446020A (en) * | 2013-09-02 | 2013-12-18 | 上海应用技术学院 | Cosmetics pigment composition containing safflower natural pigment extract and preparation method thereof |
| CN106189352A (en) * | 2016-07-19 | 2016-12-07 | 广州中大南沙科技创新产业园有限公司 | A kind of extracting method of Carthamus yellow |
-
2001
- 2001-09-05 CN CN 01131268 patent/CN1205216C/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300161C (en) * | 2003-09-22 | 2007-02-14 | 浙江永宁制药厂 | Yellow pigment of safflower preparation method and application |
| CN1813709B (en) * | 2005-01-31 | 2012-04-18 | 浙江永宁药业股份有限公司 | Safflower yellow dropping pill, and its preparing method and use |
| CN1301707C (en) * | 2005-03-18 | 2007-02-28 | 邹巧根 | Danhong freeze dried powder injection agent and its preparation method |
| CN102771885A (en) * | 2011-05-13 | 2012-11-14 | 湖北中烟工业有限责任公司 | Production method of food pigment granules special for coloring tobacco sheets |
| CN102771885B (en) * | 2011-05-13 | 2015-05-06 | 湖北中烟工业有限责任公司 | Production method of food pigment granules special for coloring tobacco sheets |
| CN102657691A (en) * | 2012-06-02 | 2012-09-12 | 悦康药业集团安徽天然制药有限公司 | Extraction process of carthamin yellow |
| CN103127197A (en) * | 2013-03-21 | 2013-06-05 | 悦康药业集团有限公司 | Preparation method of freeze-drying preparation for safflower yellow injection |
| CN103127197B (en) * | 2013-03-21 | 2015-02-18 | 悦康药业集团有限公司 | Preparation method of freeze-drying preparation for safflower yellow injection |
| CN103446020A (en) * | 2013-09-02 | 2013-12-18 | 上海应用技术学院 | Cosmetics pigment composition containing safflower natural pigment extract and preparation method thereof |
| CN103446020B (en) * | 2013-09-02 | 2015-03-04 | 上海应用技术学院 | Cosmetics pigment composition containing safflower natural pigment extract and preparation method thereof |
| CN106189352A (en) * | 2016-07-19 | 2016-12-07 | 广州中大南沙科技创新产业园有限公司 | A kind of extracting method of Carthamus yellow |
| CN106189352B (en) * | 2016-07-19 | 2018-06-26 | 广州中大南沙科技创新产业园有限公司 | A kind of extracting method of carthamin yellow |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1205216C (en) | 2005-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101195647B (en) | Hydroxyl carthamus tinctorius yellow colour A, preparation method and application thereof | |
| CN101396384B (en) | Asiatic centella extract and preparation methode thereof | |
| CN102772500B (en) | Relingqing Polygonum capitatum Buch-Ham ex D.Don raw material extract with anti-inflammatory action | |
| CN1205216C (en) | Safflower lyochrome rich in carthamin A, its preparing process, its preparation and its medical usage | |
| CN102068445A (en) | Method for preparing pulsatilla chinensis (Bunge) Regel saponin matter and application of pulsatilla chinensis (Bunge) Regel saponin matter in preparation of antischistosomal medicament | |
| CN101234147B (en) | Method of preparing total flavones of tropaeolum for injections | |
| CN102805767B (en) | Heat stranguria removal granule raw material polygonum capitatum extract with anti-gonococcus effect | |
| CN1229324C (en) | Extraction process of tanshin general phenolic acid and its prepn and use | |
| CN1709417A (en) | Ainsliaea fragrans champ extract and its preparing method | |
| CN110194758B (en) | Method for separating and purifying aristolochic acid compounds from caulis Aristolochiae Manshuriensis | |
| CN1682971A (en) | Compound isatis root freeze-dried powder injection and its preparing method | |
| CN113440547B (en) | Method for separating and purifying Japanese thistle herb total glycosides by adopting macroporous resin series dynamic axial compression column | |
| CN101658542B (en) | Soft-lithospermum total phenolic acid and use thereof in pharmacy | |
| CN1264530C (en) | Freeze-dried 'Shenqifuzheng' powder for injection and its preparing process | |
| CN1973853A (en) | Hemostatic and analgetic medicine composition and its prepn process | |
| CN101468196B (en) | Method for preparing tetrandra and astragalus decoction preparation | |
| CN101254209A (en) | Calf spleen extract injection prepared by inphase opposition column chromatography and preparation thereof | |
| CN101618069B (en) | Capsule preparation for treating bruise as well as bleeding and easing pain and preparation method and use thereof | |
| CN110448651B (en) | Preparation method of Tibetan traditional Chinese medicine composition for treating liver diseases, composition and granules containing composition | |
| CN1303052C (en) | Process for preparing Danshensu | |
| CN1278703C (en) | Freeze-dried powder and injection preparation of red sage root and safflower, and preparation method | |
| CN1220489C (en) | Freeze-dried Danhong powder injection for injection and its preparing method | |
| CN1872101A (en) | Distillage of Ardisia chinensis Benth of possessing function of antivirus, distilling method and application | |
| CN1180781C (en) | Bupleurum flavone composition for resisiting influenza virus and its prepn. | |
| CN1768770A (en) | Quality control method of agavaceae extract medicinal formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| ASS | Succession or assignment of patent right |
Owner name: CHANGCHUN SANZHEN INDUSTRY CO.,LTD. Free format text: FORMER OWNER: SHANDONG GREEN LEAF PHARMACEUTICAL CO., LTD. Effective date: 20030131 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20030131 Applicant after: Sanzhen Industrial Co., Ltd., Changchun Applicant before: Luye Pharmaceutical Co., Ltd., Shandong |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG LVYE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHANGCHUN SANZHEN INDUSTRY CO.,LTD. Effective date: 20100129 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100129 Address after: No. 9, Po Yuen Road, Laishan District, Yantai, Shandong Patentee after: Shandong Luye Pharma Co., Ltd. Address before: Changchun City People's Avenue No. 179-1 south tower C 3 layer Patentee before: Sanzhen Industrial Co., Ltd., Changchun |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050608 Termination date: 20200905 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |